The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Translation Of Glaucoma Blindness Genes To Improve Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$856,795.00
Summary
Glaucoma is a common cause of irreversible blindness. It is currently difficult to predict which patients with the earliest signs of glaucoma will develop blinding stages of the disease. This study will investigate how genes and eye measurements can be used to predict the risk of developing severe glaucoma in people with early signs of disease. This will ensure that high risk individuals can access treatment early, while those at low risk can be spared unnecessary treatment and seen less often.
Drinking from the fire hose - Making sense of high density genetic and genomic data. The project will improve our understanding of the genetic component of common complex diseases such as cancer. Identification of genetic variants underlying disease risk is currently one of the primary means for increasing our understanding of the biochemical and developmental pathways involved. Genetic studies rely on sophisticated statistical and computational (bioinformatics) techniques. This project centres ....Drinking from the fire hose - Making sense of high density genetic and genomic data. The project will improve our understanding of the genetic component of common complex diseases such as cancer. Identification of genetic variants underlying disease risk is currently one of the primary means for increasing our understanding of the biochemical and developmental pathways involved. Genetic studies rely on sophisticated statistical and computational (bioinformatics) techniques. This project centres on the development, refinement and application of novel statistical analysis methods in genetics. Future advances in statistical and computational methods are essential if we are to exploit the large volumes of genome data now being generated to help develop diagnostics and interventions to improve public health.Read moreRead less
Dissecting The Great Ophthalmic Masquerade: The Global Giant Cell Arteritis Genomics Consortium.
Funder
National Health and Medical Research Council
Funding Amount
$583,269.00
Summary
Giant cell arteritis (GCA) is the most common form of vasculitis in people over 50 years of age. If untreated it can cause catastrophic complications including blindness, though this can be prevented if treated early. Although there is clear evidence for a role of genetic factors in GCA, these have been little studied. We have established an Australian-led International consortium, with clinical, basic science and statistical expertise to thoroughly investigate this devastating disease.
Understanding progressive vision loss in the eye disease glaucoma. Glaucoma is the second leading cause of irreversible vision loss in elderly Australians, although determining treatment failure is currently very dif?cult. This project will radically improve the measurement of glaucoma progression and treatment failure. We will also address fundamental questions regarding how glaucoma destroys vision.
Improving Patient Management Pathways In Age-Related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$181,065.00
Summary
Age related macular degeneration (AMD) is the most common cause of vision impairment in Australians aged over 50 years. In recent years, there have been a number of diagnostic tests and new interventions developed for AMD, but it has proven challenging to communicate this information to all primary eye care practitioners. This project will investigate the reasons management guidelines are not always being followed, and develop online training to provide direct bench-to-bedside AMD education.
High Penetrance Deleterious Mutations In Blinding Glaucoma
Funder
National Health and Medical Research Council
Funding Amount
$1,345,055.00
Summary
This project aims to identify the genes most commonly mutated in individuals with advanced glaucoma. Identification of such genes will lead to improved understanding of glaucoma pathogenesis, a better ability to predict risk, and the identification of drug targets for novel therapies.
Linking Research, Policy And Health Services To Build A Better Evidence Base For Workplace
Funder
National Health and Medical Research Council
Funding Amount
$1,683,991.00
Summary
This application brings together four of Australia’s leading population and occupational health researchers to develop much needed national research capacity to reduce the burden of the largely hidden problem of occupational disease and to improve health and wellbeing in Australian workplaces. It is designed to develop a wide range of skills in a group of post-doctoral Team Investigators to improve the link between research, policy and practice. This program will address several of the National ....This application brings together four of Australia’s leading population and occupational health researchers to develop much needed national research capacity to reduce the burden of the largely hidden problem of occupational disease and to improve health and wellbeing in Australian workplaces. It is designed to develop a wide range of skills in a group of post-doctoral Team Investigators to improve the link between research, policy and practice. This program will address several of the National Health Priorities such as asthma, cancer, mental health and musculoskeletal disorders.Read moreRead less
Improving Visual Outcomes In Patients With Diabetic Macular Oedema Undergoing Cataract Surgery: A Prospective Randomised Clinical Trial (the DiMECat Trial)
Funder
National Health and Medical Research Council
Funding Amount
$187,322.00
Summary
Cataract and diabetic retinopathy are the leading causes of visual loss in patients with diabetes, but unfortunately, cataract surgery in these patients often results in a loss of vision, rather than an improvement. The purpose of this study is to improve the visual outcomes in this group of patients, through the use of new, injected medicines that are given at the time of cataract surgery, thereby potentially changing current medical practice.
A Fibroin-based Prosthetic Bruch's Membrane For The Treatment Of Age-related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$538,080.00
Summary
Our aim is to develop a new therapy for the treatment of patients with age-related macular degeneration (AMD), a leading cause of blindness in our ageing population. The novelty of our therapy resides in using a protein derived from silk fibers (fibroin), to rebuild a healthy barrier between the outermost layer of the retina and adjacent blood vessels. We expect that the findings from this study will eventually lead to better outcomes for patients with AMD.
A Genome-wide Association Scan To Identify Genetic Risk Factors For Sight Threatening Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$982,203.00
Summary
Diabetic eye disease is an important complication of diabetes that can lead to blindness. Very little is known about how diabetes causes eye disease, but genetics is known to play a role. We aim to identify genes that contribute to eye disease in diabetes patients. We will compare genes between patients with diabetes with and without severe diabetic eye disease using cutting edge genomic technology. We hope to be able to better predict risk of blindness and to move towards novel treatments.